ELTP (Elite Pharmaceuticals) Total Equity: $80.3 Mil (As of Dec. 2025)


ELTP Elite Pharmaceuticals Inc ELTP
42 GF Score
Price $0.40
GF Value $0.57
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is Elite Pharmaceuticals Total Equity?

Elite Pharmaceuticals ELTP +3.66% 42 Total Equity is $80.3 Mil as of Dec. 2025. GuruFocus rates ELTP with a GF Score™ of 42/100 and a GF Value™ of $0.57 (Modestly Undervalued). The stock has 1 warning sign investors should review.

Elite Pharmaceuticals's total equity for the quarter that ended in Dec. 2025 was $80.3 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Elite Pharmaceuticals Total Equity Historical Data

* Premium members only.

The historical data trend for Elite Pharmaceuticals's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Elite Pharmaceuticals Total Equity Chart

Elite Pharmaceuticals Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 16.15 25.22 28.96 57.58 53.52

Elite Pharmaceuticals Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 36.45 53.52 47.68 61.59 80.31
ELTP
42GF Score
Elite Pharmaceuticals Inc ELTP
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Elite Pharmaceuticals Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Elite Pharmaceuticals's Total Equity for the fiscal year that ended in Mar. 2025 is calculated as

Total Equity=Total Assets(Q: Mar. 2025 )-Total Liabilities(Q: Mar. 2025 )
=96.387-42.872
=53.5

Elite Pharmaceuticals's Total Equity for the quarter that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=126.413-46.099
=80.3

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of $80.3 Mil mean?
Elite Pharmaceuticals (ELTP) has a Total Equity of $80.3 Mil as of Dec. 2025. The total amount of equity as record on a company's balance sheet. View historical data for Elite Pharmaceuticals and its competitors.
Is Elite Pharmaceuticals' Total Equity too high?
Elite Pharmaceuticals' current Total Equity is $80.3 Mil. Overall, Elite Pharmaceuticals has a GF Score™ of 42/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Elite Pharmaceuticals' Total Equity compare to SIGA and ORGO?
Elite Pharmaceuticals' Total Equity of $80.3 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Drug Manufacturers company?
A good Total Equity depends on the Drug Manufacturers industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Elite Pharmaceuticals and its competitors. Elite Pharmaceuticals's current Total Equity is $80.3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Elite Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Elite Pharmaceuticals (ELTP) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.57, compared to a current price of $0.40 — trading 30% below its estimated fair value. The current Total Equity is $80.3 Mil. Elite Pharmaceuticals' overall GF Score™ is 42/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Elite Pharmaceuticals (ELTP), the current Total Equity is $80.3 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Elite Pharmaceuticals (ELTP) Overvalued in 2026?

Based on GuruFocus' analysis, Elite Pharmaceuticals stock appears to be undervalued. The current stock price of $0.40 is trading 30% below its estimated GF Value™ of $0.57. GuruFocus considers Elite Pharmaceuticals to be Modestly Undervalued.

Key valuation signals for ELTP:

  • Total Equity: $80.3 Mil
  • GF Value™: $0.57 vs. price of $0.40 (30% below fair value)
  • GF Score™: 42/100 with 1 warning sign

No single metric tells the full story. See the ELTP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Elite Pharmaceuticals Business Description

Address 165 Ludlow Avenue, Northvale, NJ, USA, 07647
Elite Pharmaceuticals Inc is a pharmaceutical company. It is principally engaged in the development and manufacture of oral, controlled-release products, using proprietary know-how and technology. The company's operating segment includes Abbreviated New Drug Applications (ANDA) and New Drug Applications (NDA). It generates maximum revenue from the ANDA segment. The company focuses on developing pain management products; manufacturing a line of generic pharmaceutical products with approved Abbreviated New Drug Applications; developing additional generic pharmaceutical products; development of other products in its pipeline including the products with its partners; and commercialization of new products.
42GF Score

Get the complete analysis for ELTP

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.40
Price
$0.57
GF Value